Bolt Biotherapeutics
BOLT
34 hedge funds and large institutions have $25.5M invested in Bolt Biotherapeutics in 2023 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 8 closing their positions.
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
0.08% less ownership
Funds ownership: 3.31% → 3.23% (-0.08%)
15% less funds holding
Funds holding: 40 → 34 (-6)
20% less capital invested
Capital invested by funds: $32.1M → $25.5M (-$6.56M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
75% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$273K |
| 2 |
Morgan Stanley
New York
|
+$154K |
| 3 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
+$45.9K |
| 4 |
NM
Newtyn Management
New York
|
+$24.4K |
| 5 |
Squarepoint
New York
|
+$19.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$364K |
| 2 |
Renaissance Technologies
New York
|
-$207K |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$203K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$162K |
| 5 |
Millennium Management
New York
|
-$84.3K |
BOLT Hedge Fund Activity: Q3 2023 in Review
34 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Bolt Biotherapeutics (BOLT) for Q3 2023, worth a combined $25.5M — down 20% from $32.1M a quarter earlier.
Sellers outnumbered buyers: 8 funds closed out of BOLT and 2 opened new positions — a net loss of 6 holders — while 7 trimmed existing stakes and 8 added.
The largest buyer was Tang Capital Management, adding an estimated $273K. The largest seller was Goldman Sachs, exiting entirely with an estimated $364K sold.
- 34 institutional investors held Bolt Biotherapeutics (BOLT) as of Q3 2023, down from 40 in Q2 2023.
- Funds reported $25.5M of Bolt Biotherapeutics stock for Q3 2023, down 20% quarter-over-quarter.
- 2 funds opened new Bolt Biotherapeutics positions in Q3 2023 and 8 closed out, a net change of -6 holders.
- The largest Bolt Biotherapeutics buyer in Q3 2023 was Tang Capital Management, an estimated $273K added.
- The largest Bolt Biotherapeutics seller in Q3 2023 was Goldman Sachs, an estimated $364K sold.
Based on aggregated 13F filings for Q3 2023.